4 Healthcare Stock Stories For Tuesday Investment Wellness

Eli Lilly and Co. (NYSE:LLY): Closing price $54.97

On Tuesday, Lilly announced that its recently completed Phase III study SQUIRE attained its primary endpoint, finding that patients suffering with stage IV metastatic squamous non-small cell lung cancer saw increased overall survival when administered necitumumab (IMC-11F8) in combination with gemcitabine and cisplatin as a first-line treatment, versus chemotherapy alone. The most common adverse events occurring more frequently in patients on the necitumumab arm were rash and hypomagnesemia. Serious, but less often, adverse events occurring more commonly on the necitumumab arm included thromboembolism.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

LLY-20130813

GlaxoSmithKline (NYSE:GSK): Closing price $52.01

The United Kingdom drugmaker has won United States regulatory approval for a daily pill against the deadly HIV infection that was developed by ViiV Healthcare Ltd., which is its joint venture with two other firms. Glaxo’s Tivicay can be used by adults with HIV who have never been treated for the virus, along with those who have previously received drugs to attack the illness. The drug, known as dolutegravir, is an integrase strand transfer inhibitor that interferes with the enzymes necessary for HIV to multiply, according to an FDA statement.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

GSK-20130813

Boston Scientific Corp. (NYSE:BSX): Closing price $11.24

Boston Scientific has concluded a public offering of $1.05-billion aggregate principal amount of its senior notes under its shelf registration statement. The public offering is comprised of $600 million of 2.650-percent notes due October 1, 2018 and $450 million of 4.125-percent notes due October 1, 2023. The firm previously said that it will use the net proceeds, together with borrowings under its recent $400-million term loan facility, to redeem all or a portion of its 5.450-percent notes due June 15, 2014, of which $600 million aggregate principal amount was outstanding as of the date hereof, and 4.5-percnt notes due January 15, 2015, of which $850 million aggregate principal amount was outstanding as of the date hereof, and to pay related fees, expenses and premiums.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BSX-20130813

 Acasti Pharma Inc. (NASDAQ:ACST): Closing price $3.84

The Neptune Technologies & Bioressources Inc.’s subsidiary Acasti Pharma, announced positive results for its Phase II randomized, open-label, dose-ranging, multi-center trial, created to assess the safety and efficacy of its investigational new drug candidate CaPre in the treatment of mild to severe hypertriglyceridemia. CaPre was found to be safe and effective with significant mean triglyceride reductions above 20 percent, after 8 weeks of treatment with both daily doses of 4g and 2g.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACST-20130813

Don’t Miss: Glaxo Gets FDA Approval for This Important New HIV Drug.

More from The Cheat Sheet